PacBio Q3 revenue falls to $38.4 mln, EPS beats

Pacific Biosciences of California

05/11/2025 21:39

Overview

PacBio Q3 2025 revenue declines to $38.4 mln from $40 mln in Q3 2024

Adjusted EPS beats analyst expectations

Record consumable revenue achieved, contributing to improved gross margins

Outlook

Company expects SPRQ-Nx chemistry to reduce sequencing costs by up to 40%

PacBio aims to make long-read sequencing more economically competitive

Company expands PureTarget portfolio to support high throughput sequencing

Result Drivers

CONSUMABLE REVENUE - Record consumable revenue achieved, contributing to improved gross margins

CHINA APPROVAL - Sequel II CNDx system received Class III Medical Device Registration approval in China

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Adjusted EPS
Beat
-$0.12
-$0.16 (4 Analysts)
Q3 EPS
-$0.13
Q3 Adjusted Net Income
Beat
-$36.85 mln
-$45.28 mln (5 Analysts)
Q3 Adjusted Gross Profit
$16.16 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 7 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Pacific Biosciences of California Inc is $1.65, about 21.2% below its November 4 closing price of $2.00

Press Release: ID:nGNX9Ln55v

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)